Overview

A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients

Status:
Completed

Trial end date:
2018-06-01

Target enrollment:

Participant gender:

Summary

TJO-002 or Acitve Control was administered on primary open-angle glaucoma or ocular hypertension patients for 12 weeks. This clinical trial study has hypothesize TJO-002 administration groups are not inferior to Active control administration groups.

Phase:

Phase 3

Details

Lead Sponsor:

Taejoon Pharmaceutical Co., Ltd.

Treatments:

Latanoprost